Excess BMI in childhood:A modifiable risk factor for type 1 diabetes development?

Autor: Ferrara, CT, Geyer, SM, Liu, Y-F, Evans-Molina, C, Libman, IM, Besser, R, Becker, DJ, Rodriguez, H, Moran, A, Gitelman, SE, Redondo, MJ, Group, Type 1 Diabetes TrialNet Study

Publikováno v: Ferrara, C T, Geyer, S M, Liu, Y-F, Evans-Molina, C, Libman, I M, Besser, R, Becker, D J, Rodriguez, H, Moran, A, Gitelman, S E, Redondo, M J 2017, ' Excess BMI in childhood : A modifiable risk factor for type 1 diabetes development? ', Diabetes Care, vol. 40, no. 5, pp. 698-701 . https://doi.org/10.2337/dc16-2331
Diabetes care, vol 40, iss 5
Diabetes Care

OBJECTIVE We aimed to determine the effect of elevated BMI over time on the progression to type 1 diabetes in youth. RESEARCH DESIGN AND METHODS We studied 1,117 children in the TrialNet Pathway to Prevention cohort (autoantibody-positive relatives o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9197f468a9bb2f03f256927b5d6aeb1f
https://kclpure.kcl.ac.uk/ws/files/74105957/Excess_body_mass_index_FERRARA_Publishedonline20April2017_GREEN_AAM.pdf

Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report

Autor: Gitelman, Stephen, Wherrett, DK, Chiang, JL, Delamater, AM, Dimeglio, LA, Gitelman, SE, Gottlieb, PA, Herold, KC, Lovell, DJ, Orchard, TJ, Ryan, CM

Publikováno v: Gitelman, Stephen; Wherrett, DK; Chiang, JL; Delamater, AM; Dimeglio, LA; Gitelman, SE; et al.(2015). Defining Pathways forDevelopment of Disease-Modifying Therapies in Children With Type 1 Diabetes: A Consensus Report. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/4wm074bk

© 2015 by the American Diabetes Association.Emerging data suggest that type 1 diabetes is a more aggressive disease in children than in adults, with important differences in pathophysiology and clinical course. Therefore, the efficacy of disease-mod

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::415d6446b172fb9a23a3a4079a0180b4
http://www.escholarship.org/uc/item/4wm074bk

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders

Autor: Herold, KC, Gitelman, SE, Ehlers, MR, Gottlieb, PA, Greenbaum, CJ, Hagopian, W, Boyle, KD, Keyes-Elstein, L, Aggarwal, S, Phippard, D, Sayre, PH, McNamara, J, Bluestone, JA

Publikováno v: Diabetes Technology and Therapeutics, vol 16, iss SUPPL. 1
Herold, KC; Gitelman, SE; Ehlers, MR; Gottlieb, PA; Greenbaum, CJ; Hagopian, W; et al.(2014). Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes Technology and Therapeutics, 16(SUPPL. 1), S86-S87. doi: 10.1089/dia.2014.1510. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/0bc480zj
Herold, KC; Gitelman, SE; Ehlers, MR; Gottlieb, PA; Greenbaum, CJ; Hagopian, W; et al.(2013). Teplizumab (Anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: Metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes, 62(11), 3766-3774. doi: 10.2337/db13-0345. UCSF: Retrieved from: http://www.escholarship.org/uc/item/2t80r87v

Trials of immune therapies in new-onset type 1 diabetes (T1D) have shown success, but not all subjects respond, and the duration of response is limited. Our aim was to determine whether two courses of teplizumab, an Fc receptor-nonbinding anti-CD3 mo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::a802baca9c3a40eee13c3101f723528b
https://escholarship.org/uc/item/0bc480zj

Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: Follow-up 1 year aftercessation of treatment

Autor: Gitelman, Stephen, Orban, T, Bundy, B, Becker, DJ, DiMeglio, LA, Gitelman, SE, Goland, R, Gottlieb, PA, Greenbaum, CJ, Marks, JB, Monzavi, R

Publikováno v: Gitelman, Stephen; Orban, T; Bundy, B; Becker, DJ; DiMeglio, LA; Gitelman, SE; et al.(2014). Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: Follow-up 1 year aftercessation of treatment. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/5bv4c8fx

OBJECTIVE: We previously reported that 2 years of costimulation modulation with abatacept slowed decline of β-cell function in recent-onset type 1 diabetes (T1D). Subsequently, abatacept was discontinued and subjects were followed to determine wheth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::7a8c5a61f2252b6fa27d18058d514af7
http://www.escholarship.org/uc/item/5bv4c8fx

A cross-sectional study of osteocalcin and body fat measures among obese adolescents

Autor: Gitelman, Stephen, Lenders, CM, Lee, PDK, Feldman, HA, Wilson, DM, Abrams, SH, Gitelman, SE, Klish, WJ, Wertz, MS, Taylor, GA, Alongi, RT

Publikováno v: Gitelman, Stephen; Lenders, CM; Lee, PDK; Feldman, HA; Wilson, DM; Abrams, SH; et al.(2013). A cross-sectional study of osteocalcin and body fat measures among obese adolescents. UC San Francisco: Retrieved from: http://www.escholarship.org/uc/item/3hh8w71s

Osteocalcin (OCN), a marker of osteoblast activity, has been implicated in the regulation of energy metabolism by the skeleton and thus may affect body fat measures. Objective: To examine the relationships of OCN to body fat measures and whether they

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od_______325::42913692850fb856a5df245b6f0426f4
http://www.escholarship.org/uc/item/3hh8w71s